4D Molecular Therapeutics, Inc. - 8-K Filing

4D Molecular Therapeutics reports Q3 2026 net loss of $78.1 million and announces completion of randomization for 4FRONT-2 Phase 3 trial. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:11 UTC

Tickers: $FDMT

Read the full article at SEC EDGAR

More Regulatory news

FACT II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Marblegate Capital Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Greenland Mines Ltd - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Pinnacle Acquisition Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:45 UTC
SUTRO BIOPHARMA, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Aeluma, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
ASTEC INDUSTRIES INC - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
Live Oak Bancshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:44 UTC